Our latest publication in Nature Communication
Have a look at our latest publication in Nature Communication about autoantibodies against GPCR! 2018 Naturecommunication https://www.nature.com/articles/s41467-018-07598-9
CellTrend has received the patent for auto-antibodies against VEGF
Vascular endothelial growth factor (VEGF) plays a central role in tumor growth, metastasis and angiogenesis. Various drugs (such as Avastin (R)) interfere tumor growth at this pathway. CellTrend were the first to describe auto-antibodies against VEGF and measures them with an validated ELISA. This discovery enables new strategies for personalization of tumor therapy and may…